BioCentury | May 25, 2015
Strategy

You better you bet

...last clinical HCV NS5A protein inhibitor - EDP-239 is in Phase I. According to Enanta, EDP-239...
BioCentury | Jan 19, 2015
Clinical News

EDP-788: Development discontinued

...2011 & Sept. 9, 2013). Enanta said it will focus on its HCV candidates, including EDP-239...
...infection with infectious disease candidates in indications with greater commercial opportunities than Gram-positive bacterial infections. EDP-239...
BioCentury | Oct 27, 2014
Company News

Enanta, AbbVie deal

...will instead fund development of its in-house HCV candidates and other infectious disease programs, including EDP-239...
BioCentury | Oct 22, 2014
Company News

Enanta falls on revised AbbVie deal

...its in-house HCV candidates and other infectious disease programs. The company recently regained rights to EDP-239...
BioCentury | Oct 6, 2014
Company News

Enanta, Novartis deal

...Enanta said Novartis will return rights to the biotech's EDP-239 , an HCV non-structural protein 5A...
...I testing, as the pharma exits the HCV business. Novartis acquired exclusive, worldwide rights to EDP-239...
...in January 2013 triggered by Novartis starting dosing in the first Phase I trial of EDP-239...
BioCentury | Oct 2, 2014
Company News

Novartis returning Enanta's HCV compound

...Enanta Pharmaceuticals Inc. (NASDAQ:ENTA) saidNovartis AG (NYSE:NVS; SIX:NOVN) will return rights to the biotech's EDP-239...
...I testing, as the pharma exits the HCV business. Novartis acquired exclusive, worldwide rights to EDP-239...
BioCentury | Sep 1, 2014
Clinical News

Alisporivir: Phase I started

...open-label Phase I trial evaluating alisporivir in combination with EDP-239 in about 42 healthy volunteers. EDP-239...
...II testing to treat HCV infection. Novartis has exclusive, worldwide rights to develop and commercialize EDP-239...
BioCentury | Sep 1, 2014
Clinical News

EDP-239: Phase I

...open-label Phase I trial evaluating alisporivir in combination with EDP-239 in about 42 healthy volunteers. EDP-239...
...II testing to treat HCV infection. Novartis has exclusive, worldwide rights to develop and commercialize EDP-239...
...15, 2010). Enanta Pharmaceuticals Inc. (NASDAQ:ENTA), Watertown, Mass. Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Product: EDP-239...
BioCentury | Sep 2, 2013
Clinical News

EDP-239: Phase I started

...that Novartis began a double-blind, placebo-controlled, U.S. Phase I trial to evaluate single doses of EDP-239...
...about 28 patients. Last year, Enanta granted Novartis exclusive, worldwide rights to develop and commercialize EDP-239...
...27, 2012). Enanta Pharmaceuticals Inc. (NASDAQ:ENTA), Watertown, Mass. Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Product: EDP-239...
BioCentury | Aug 6, 2012
Strategy

Freedom to deal Strategy

...regimen in HCV. Then in February, Enanta Pharmaceuticals Inc. granted Novartis exclusive, worldwide rights to EDP-239...
Items per page:
1 - 10 of 13